- Barriers to treatment of failed or interferon ineligible patients in the era of DAA: single center study
-
Seo KI, Yun BC, Li WJ, Lee SU, Han BH, Park ET
- KMID: 2412117
- Clin Mol Hepatol.
- 2017 Mar;23(1):74-79.
- doi: 10.3350/cmh.2016.0052
BACKGROUND/AIMS: Interferon-based treatment is not appropriate for a large number of patients with chronic hepatitis C for various medical and social reasons. Newly developed directly acting antivirals (DAAs) have been... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy and safety of daclatasvir plus asunaprevir for Korean patients with HCV genotype Ib infection: a retrospective multi-institutional study
-
Cho BW, Kim SB, Song IH, Lee SH, Kim HS, Lee TH, Kang YW, Kim SH, Lee BS, Chae HB
- KMID: 2412114
- Clin Mol Hepatol.
- 2017 Mar;23(1):51-56.
- doi: 10.3350/cmh.2016.0053
BACKGROUND/AIMS: The combination of daclatasvir (DCV) and asunaprevir (ASV) has demonstrated a high sustained virologic response at 12 weeks (SVR12) and a low rate of adverse events in previous clinical... -
- CITED
-
- Close
- SHARE
-
- Close
- Management of direct antiviral agent failures
-
Buti M, Esteban R
- KMID: 2373146
- Clin Mol Hepatol.
- 2016 Dec;22(4):432-438.
- doi: 10.3350/cmh.2016.0107
The current standard of care for patients with chronic hepatitis C virus (HCV) infection is a combination of direct-acting antiviral agents (DAAs). Most HCV patients treated with these drugs achieve... -
- CITED
-
- Close
- SHARE
-
- Close
- Immunosuppression status of liver transplant recipients with hepatitis C affects biopsy-proven acute rejection
-
Kim JM, Lee KW, Song GW, Jung BH, Lee HW, Yi NJ, Kwon CD, Hwang S, Suh KS, Joh JW, Lee SK, Lee SG
- KMID: 2373137
- Clin Mol Hepatol.
- 2016 Sep;22(3):366-371.
- doi: 10.3350/cmh.2016.0022
BACKGROUND/AIMS: The relationship between patient survival and biopsy-proven acute rejection (BPAR) in liver transplant recipients with hepatitis C remains unclear. The aims of this study were to compare the characteristics... -
- CITED
-
- Close
- SHARE
-
- Close
- KASL clinical practice guidelines: management of hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 2363030
- Clin Mol Hepatol.
- 2016 Mar;22(1):76-139.
- doi: 10.3350/cmh.2016.22.1.76
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea
-
Cho Y, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ
- KMID: 2359817
- Clin Mol Hepatol.
- 2015 Dec;21(4):358-364.
- doi: 10.3350/cmh.2015.21.4.358
BACKGROUND/AIMS: The previous standard treatment for chronic hepatitis C (CHC) patients, comprising a combination of pegylated interferon (IFN) and ribavirin, was associated with suboptimal efficacy and severe adverse reactions. A... -
- CITED
-
- Close
- SHARE
-
- Close
- New Therapeutic Agent for Chronic Hepatitis C: Direct Acting Agent
-
Chae HB
- KMID: 2373305
- Korean J Gastroenterol.
- 2015 Jul;66(1):5-9.
- doi: 10.4166/kjg.2015.66.1.5
Peg-interferon and ribavirin has been the standard therapy of chronic hepatitis C for the past 15 years in Korea. However, the treatment paradigm is changing. Direct acting agents (DAAs) are... -
- CITED
-
- Close
- SHARE
-
- Close
- Highly effective peginterferon alpha-2a plus ribavirin combination therapy for chronic hepatitis C in hemophilia in Korea
-
Yang SY, Lee HW, Lee YJ, Park SJ, Yoo KY, Kim HJ
- KMID: 2164362
- Clin Mol Hepatol.
- 2015 Jun;21(2):125-130.
- doi: 10.3350/cmh.2015.21.2.125
BACKGROUND/AIMS: Chronic hepatitis C (CHC) is a major comorbidity in patients with hemophilia. However, there are no published data on the efficacy of antiviral therapy in Korea. We assessed the... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis C virus-induced hepatocellular carcinoma
-
Goossens N, Hoshida Y
- KMID: 2164359
- Clin Mol Hepatol.
- 2015 Jun;21(2):105-114.
- doi: 10.3350/cmh.2015.21.2.105
Hepatitis C virus (HCV) is a leading etiology of hepatocellular carcinoma (HCC). The interaction of HCV with its human host is complex and multilayered; stemming in part from the fact... -
- CITED
-
- Close
- SHARE
-
- Close
- A Polymorphism in the Microsomal Triglyceride Transfer Protein Can Predict the Response to Antiviral Therapy in Egyptian Patients with Chronic Hepatitis C Virus Genotype 4 Infection
-
Saad Y, Shaker O, Nassar Y, Ahmad L, Said M, Esmat G
- KMID: 2070084
- Gut Liver.
- 2014 Nov;8(6):655-661.
- doi: 10.5009/gnl13374
BACKGROUND/AIMS: A polymorphism in the microsomal triglyceride transfer protein (MTP) is associated with hepatic fibrosis, and carriers showed higher levels of steatosis, higher levels of hepatitis C virus (HCV) RNA... -
- CITED
-
- Close
- SHARE
-
- Close
- KASL clinical practice guidelines: Management of Hepatitis C
-
The Korean Association for the Study of the Liver (KASL)
- KMID: 1788561
- Clin Mol Hepatol.
- 2014 Jun;20(2):89-136.
- doi: 10.3350/cmh.2014.20.2.89
No abstract available. -
- CITED
-
- Close
- SHARE
-
- Close
- The impact of pegylated interferon and ribavirin combination treatment on lipid metabolism and insulin resistance in chronic hepatitis C patients
-
Jung HJ, Kim YS, Kim SG, Lee YN, Jeong SW, Jang JY, Lee SH, Kim HS, Kim BS
- KMID: 1737597
- Clin Mol Hepatol.
- 2014 Mar;20(1):38-46.
- doi: 10.3350/cmh.2014.20.1.38
BACKGROUND/AIMS: Lipid profile and insulin resistance (IR) are associated with hepatitis C virus (HCV) and may predict the chronic hepatitis C (CHC) treatment response. The aim of this study was... -
- CITED
-
- Close
- SHARE
-
- Close
- Predicting factors of present hepatitis C virus infection among patients positive for the hepatitis C virus antibody
-
Lee CH, Shin HP, Lee JI, Joo KR, Cha JM, Jeon JW, Lim JU, Min JK, Kim DH, Kang SW, Joung HJ
- KMID: 1730883
- Clin Mol Hepatol.
- 2013 Dec;19(4):376-381.
- doi: 10.3350/cmh.2013.19.4.376
BACKGROUND/AIMS: To identify the predicting factors of present hepatitis C virus (HCV) infection among patients with positivity for antibodies to HCV (anti-HCV). METHODS: We analyzed patients who showed positive enzyme immunoassay... -
- CITED
-
- Close
- SHARE
-
- Close
- Occult Hepatitis B Virus Infection in Chronic Hepatitis C
-
Jang JY, Park EJ
- KMID: 1707197
- Korean J Gastroenterol.
- 2013 Sep;62(3):154-159.
- doi: 10.4166/kjg.2013.62.3.154
Occult HBV infection is defined as the presence of HBV DNA in the liver (with or without detectable or undetectable HBV DNA in the serum) of individuals testing negative for... -
- CITED
-
- Close
- SHARE
-
- Close
- The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean
-
Kim JS, Ahn SM, Jung YK, Kwon OS, Kim YS, Choi DJ, Kim JH
- KMID: 1793028
- J Korean Med Sci.
- 2013 Aug;28(8):1213-1219.
- doi: 10.3346/jkms.2013.28.8.1213
Two variants of the inosine triphosphatase (ITPA: rs1127354, rs7270101) gene cause ITPA deficiency and protect against the hemolytic toxicity of ribavirin. We investigated the clinical significance of ITPA variants in... -
- CITED
-
- Close
- SHARE
-
- Close
- Advanced fibrosis is not a negative pretreatment predictive factor for genotype 2 or 3 chronic hepatitis C patients
-
Lee HS, Kweon YO, Tak WY, Park SY, Kang EJ, Lee YL, Yang HM, Park HW
- KMID: 1776802
- Clin Mol Hepatol.
- 2013 Jun;19(2):148-155.
- doi: 10.3350/cmh.2013.19.2.148
BACKGROUND/AIMS: Chronic hepatitis C patients with advanced fibrosis have unsatisfactory sustained virological response (SVR) rates. Few data demonstrating the efficacy of combination therapy in chronic hepatitis C patients with advanced... -
- CITED
-
- Close
- SHARE
-
- Close
- High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice
-
Heo NY, Lim YS, Lee HC, Lee YS, Kim KM, Byun KS, Han KH, Lee KS, Paik SW, Yoon SK, Suh DJ
- KMID: 1493576
- Clin Mol Hepatol.
- 2013 Mar;19(1):60-69.
- doi: 10.3350/cmh.2013.19.1.60
BACKGROUND/AIMS: Identifying the impact of a patient's ethnicity on treatment responses in clinical practice may assist in providing individualized treatment regimens for chronic hepatitis C (CHC). The effectiveness of standard... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis C virus: virology and life cycle
-
Kim CW, Chang KM
- KMID: 1493570
- Clin Mol Hepatol.
- 2013 Mar;19(1):17-25.
- doi: 10.3350/cmh.2013.19.1.17
Hepatitis C virus (HCV) is a positive sense, single-stranded RNA virus in the Flaviviridae family. It causes acute hepatitis with a high propensity for chronic infection. Chronic HCV infection can... -
- CITED
-
- Close
- SHARE
-
- Close
- Hepatitis C virus and hepatocarcinogenesis
-
Jeong SW, Jang JY, Chung RT
- KMID: 1410890
- Clin Mol Hepatol.
- 2012 Dec;18(4):347-356.
- doi: 10.3350/cmh.2012.18.4.347
Hepatitis C virus (HCV) is an RNA virus that is unable to integrate into the host genome. However, its proteins interact with various host proteins and induce host responses. The... -
- CITED
-
- Close
- SHARE
-
- Close
- Efficacy of Peginterferon and Ribavirin Combination Therapy of Chronic Hepatitis C: A Pooled Analysis
-
Park SY, Rim MY, Yo IK, Ha MS, Kim JS, Lee JW, Jung YK, Kwon OS, Kim YS, Choi DJ, Kim JH
- KMID: 1775796
- Korean J Gastroenterol.
- 2012 Nov;60(5):306-314.
- doi: 10.4166/kjg.2012.60.5.306
BACKGROUND/AIMS: A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in... -
- CITED
-
- Close
- SHARE
-
- Close
